Modality
Cell Therapy
MOA
CGRPant
Target
HER2
Pathway
T-cell
LNGA
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
~Jan 2021
→ ~Apr 2022
Phase 2
Jul 2022
→ Jun 2025
Phase 2Current
NCT05502367
2,302 pts·GA
2023-07→TBD·Active
NCT04182321
2,758 pts·GA
2022-07→2025-06·Recruiting
5,060 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-06-229mo agoPh3 Readout· GA
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
P2/3
Recruit…
P2/3
Active
Catalysts
Ph3 Readout
2025-06-22 · 9mo ago
GA
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05502367 | Phase 2/3 | GA | Active | 2302 | NT-proBNP |
| NCT04182321 | Phase 2/3 | GA | Recruiting | 2758 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| Rilufotisoran | Samsung Biologics | NDA/BLA | FXIa |